DraftKings (NASDAQ: DKNG) Analyst Report

April 27, 2020 Research Notes

Analyst Notes coming soon!

News

Logiq (OTC: LGIQ) Expands Affordable Media Buying to Asia Pacific for Any Size Agency or Brand

July 30, 2021

NEW YORK, July 21, 2021 — Logiq, Inc. (NEO: LGIQ) (OTCQX: LGIQ), a global provider of award-winning e-commerce and fintech solutions, has expanded its Logiq Digital Marketing™ (LDM) platform to include direct media buying access to web, mobile and connected TV (CTV), and audio media providers across the Asia Pacific [...]
News

Tetra Bio-Pharma (OTC: TBPMF) Files PCT Patent Application for Cannabis Plant Residue

July 29, 2021

OTTAWA, ON, July 29, 2021 – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No. PCT/CA2021/050886, with a filing [...]
News

Logiq (OTC: LGIQ) Teams with GumGum to Bring MRC-Accredited Contextual Targeting and Brand Safety to E-Commerce Marketers

July 28, 2021

NEW YORK, July 28, 2021 — Logiq, Inc. (NEO: LGIQ) (OTCQX: LGIQ), a global provider of award-winning e-commerce and fintech solutions, has partnered with GumGum, a global media and contextual intelligence company, to provide e-commerce marketers a powerful targeting solution for their digital advertising campaigns. GumGum will offer its contextual intelligence solution, Verity™, [...]
News

Logiq (OTC: LGIQ) Announces Exercise of Over-Allotment Option in Initial Public Offering

July 27, 2021

NEW YORK, July 27, 2021 — Logiq, Inc. (“Logiq” or the “Company”) (NEO: LGIQ) (OTCQX: LGIQ), a global provider of award-winning e-commerce and fintech solutions, is pleased to announce the partial exercise of the over-allotment option in conjunction with the Company’s C$5,929,302 initial public offering (the “Offering”) of units of [...]
News

Tetra Bio-Pharma (OTC: TBPMF) Accelerates REBORN1© Trial

July 12, 2021

Ethics Committee approves REBORN1© protocol amendment allowing for the addition of two immediate release oral opioids to be compared against QIXLEEF™. REBORN1© is the first of its kind proof-of-concept phase 2 study comparing a cannabinoid-based drug, QIXLEEF™, to immediate release oral opioid for the treatment of breakthrough cancer pain. QIXLEEF™ [...]